Estimation of treatment effects and model diagnostics with two-way time-varying treatment switching: an application to a head and neck study

Treatment switching frequently occurs in clinical trials due to ethical reasons. Intent-to-treat analysis without adjusting for switching yields biased and inefficient estimates of the treatment effects. In this paper, we propose a class of semiparametric semi-competing risks transition survival models to accommodate two-way time-varying switching. Theoretical properties of the proposed method are examined. An efficient expectation-maximization algorithm is derived to obtain maximum likelihood estimates and model diagnostic tools. Existing software is used to implement the algorithm. Simulation studies are conducted to demonstrate the validity of the model. The proposed method is further applied to data from a clinical trial with patients having recurrent or metastatic squamous-cell carcinoma of head and neck.

[1]  Eric B. Laber,et al.  A Robust Method for Estimating Optimal Treatment Regimes , 2012, Biometrics.

[2]  T. Louis Finding the Observed Information Matrix When Using the EM Algorithm , 1982 .

[3]  Ian R. White,et al.  Randomization-based methods for correcting for treatment changes: examples from the Concorde trial. , 1999, Statistics in medicine.

[4]  Joseph G. Ibrahim,et al.  Missing covariates in generalized linear models when the missing data mechanism is non‐ignorable , 1999 .

[5]  J. Robins,et al.  Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log‐Rank Tests , 2000, Biometrics.

[6]  Joseph G Ibrahim,et al.  Estimating treatment effects with treatment switching via semicompeting risks models: an application to a colorectal cancer study. , 2012, Biometrika.

[7]  Donglin Zeng,et al.  New Statistical Learning Methods for Estimating Optimal Dynamic Treatment Regimes , 2015, Journal of the American Statistical Association.

[8]  Robert D. Gibbons,et al.  Estimating the Efficacy of Receiving Treatment in Randomized Clinical Trials with Noncompliance , 2001, Health Services and Outcomes Research Methodology.

[9]  Chengqing Wu,et al.  A proposed approach for analyzing post-study therapy effect in survival analysis , 2016, Journal of biopharmaceutical statistics.

[10]  Donglin Zeng,et al.  Maximum likelihood estimation in semiparametric regression models with censored data , 2007, Statistica Sinica.

[11]  S. Murphy,et al.  Optimal dynamic treatment regimes , 2003 .

[12]  Joseph G Ibrahim,et al.  Quantifying the average of the time-varying hazard ratio via a class of transformations , 2014, Lifetime Data Analysis.

[13]  I. White Estimating treatment effects in randomized trials with treatment switching , 2006, Statistics in medicine.

[14]  Ulrich Keilholz,et al.  Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. , 2015, The Lancet. Oncology.

[15]  J. Whitehead,et al.  Estimating a treatment effect in survival studies in which patients switch treatment , 2002, Statistics in medicine.

[16]  S. Chow,et al.  Statistical inference for cancer trials with treatment switching , 2005, Statistics in medicine.

[17]  J. Robins,et al.  Correcting for non-compliance in randomized trials using rank preserving structural failure time models , 1991 .

[18]  Susan A. Murphy,et al.  Introduction to SMART designs for the development of adaptive interventions: with application to weight loss research , 2014, Translational behavioral medicine.

[19]  Yu Cheng,et al.  Cumulative incidence regression for dynamic treatment regimens. , 2018, Biostatistics.

[20]  Min Zhang,et al.  Adjusting for observational secondary treatments in estimating the effects of randomized treatments. , 2013, Biostatistics.

[21]  Joseph G Ibrahim,et al.  Missing data in clinical studies: issues and methods. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Keith R. Abrams,et al.  Adjusting Survival Time Estimates in the Presence of Treatment Switching , 2014 .

[23]  Danyu Lin,et al.  Goodness-of-Fit Analysis for the Cox Regression Model Based on a Class of Parameter Estimators , 1991 .

[24]  Min Zhang,et al.  Estimating treatment effects from a randomized clinical trial in the presence of a secondary treatment. , 2012, Biostatistics.